第十一批集采竞争激烈 医保局提示理性报价

Group 1 - The eleventh batch of centralized drug procurement has seen a record number of applicants, with up to 45 companies applying for the same product, surpassing the previous record of 36 companies in the tenth batch, indicating intensified market competition [1] - A total of 480 companies submitted information for the eleventh batch of procurement, with an average of 15 companies per product among the 55 products proposed for procurement, and three products having more than 40 applicants [1][2] - The most applied products include Dihydrocodeine Injection with 45 applicants, Cefazolin Injection with 43, and Famotidine Injection with 40 [1] Group 2 - The competitive landscape is expected to lead to significant price reductions in the eleventh batch of procurement, despite measures to prevent excessive "involution" and ensure prices do not drop too low [2] - The National Healthcare Security Administration encourages qualified companies to participate actively in the procurement process while advising them to conduct cost-benefit analyses and maintain rational pricing [2][3] - The new procurement rules aim to stabilize clinical use, ensure quality, and prevent collusion and excessive competition, with changes in the pricing reference point to avoid solely relying on the lowest bid [3]